How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Document

    • Has all of the relevant evidence been taken into account?

  • Question on Document

    • Are the summaries of clinical and and cost effectiveness reasonable interpretations of the evidence?

  • Question on Document

    • Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Document

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, gender, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Cenobamate for treating focal onset seizures in epilepsy

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about cenobamate

Marketing authorisation indication

2.1 Cenobamate (Ontozry, Arvelle Therapeutics) is indicated for the 'adjunctive treatment of focal onset seizures with or without secondary generalisation in adults with epilepsy who have not been adequately controlled despite a history of treatment with at least 2 anti-epileptic medicinal products'.

Dosage in the marketing authorisation

2.2 The dosage schedule for cenobamate is available in the summary of product characteristics.

Price

2.3 Titration packs of 14-28 tablets are available in different doses ranging from 12.5 mg to 200 mg and costing between £85.54 to £165.62 per pack. Maintenance packs of 28 tablets are available in doses ranging from 50 mg to 200 mg costing £91 to £182 per pack. Estimated cost for the maintenance phase of treatment is £206 per patient per 28 days (£7.37 per day).